Lab Manager | Run Your Lab Like a Business
White moisture bubble helix on clear blue background with pure droplets

Seven Ways Osmolality Testing Improves Cell, Gene Therapy Process Development and Manufacturing

The key to improvement and success is implementing high-quality process design and parameters to ensure robustness and reproducibility

Kristeena Wright, PhD

Kristena Wright, PhD, is an applications scientist at Advanced Instruments.

ViewFull Profile.
Learn about ourEditorial Policies.
Register for free to listen to this article
Listen with Speechify

Gene and cell therapies have the potential to revolutionize the treatment of incurable diseases that are often debilitating, if not fatal. Compelling clinical successes and recent drug approvals have fueled ongoing investments in this exciting area of therapeutic research, with over 1,000 therapies in clinical trials at the end of 2019 [1].

Despite the forward momentum in the clinic, challenges remain to be solved to make these novel drugs accessible to larger patient populations. As it stands now, downstream recoveries are as low as five to 30 percent for viral vector production, depending on the process [2]. Manufacturing capacity, production yields, and supply chain logistics continue to be an area of focus for improvements to ensure customers get safe and affordable therapies.

Get training in Asset Management and earn CEUs.One of over 25 IACET-accredited courses in the Academy.
Asset Management Course

The key to improvement and success is implementing high-quality process design and process parameters to ensure robustness and reproducibility. What tools and checks can be implemented to ensure constant product and process control?

Osmolality is a measure of solute concentration and has long been considered a critical measurement in biopharma [3, 4], describing how much of a solute is present in a given solution. From simple to complex solutions, osmolality represents a consistent and valuable concentration that is insensitive to temperature and pressure, which makes it a unique and beneficial parameter during bioprocessing. Osmolality directly affects the movement of solutes across a membrane [5], making it a necessity during cell processing and any subsequent testing of injectable products. However, there are numerous uses for testing throughout any bioproduction workflow, and cell and gene therapy development will certainly benefit from additional exciting applications. Eight emerging and novel uses for osmolality testing in advanced therapy production are outlined below.

1. Media quality control (QC)

Cell media osmolality must be controlled to optimize and maintain cell growth and vector production. Media vendors measure and report the osmolality range for their solutions, and it is common for scientists to check the osmolality of each media batch against specifications to ensure the proper environment for a specific cell line or type. Whether it is later used in flasks or bioreactors, media must meet pre-determined osmolality specifications to ensure optimal cell growth and expansion [6]. Falling out of specification could result in lower growth rate and viable HEK 293 cell concentrations, leading to growth inhibition and ineffective vector production [7].

2. Culture expansion and monitoring

Osmolality continues to serve as a critical process parameter (CPP) in cell culture monitoring. Consumption of media substrates and production of waste by the cells create a dynamic osmolality profile. Additionally, different feeding and supplementation strategies as well as pH control strategies using specific gas levels will impact the osmolality differently [7, 9].

Osmolality is a critical indicator of lactate production (influenced by pH) and media base addition, ultimately impacting glycosylation in cell culture. Monitoring this parameter is essential to understanding and optimizing growth and productivity. Multiple sources have established the importance of osmolality when establishing cultivation conditions for stem cells to preserve optimal critical quality attributes (CQAs) like cell viability and productivity. Higher osmolality has been used to increase the specific production rates of waste and/or slow cell growth to maximize productivity [10, 11].

3. Transfection efficiency and osmotic shock

Achieving high transfection efficiency is critical for high viral titer yield, but it is common to see subpar transfection efficiencies in gene therapy development. Regardless of the transfection method, osmolality is important when transfecting cells with plasmid to initiate viral production. HEK293 cells, which are highly transfectable, commonly undergo polyethyenimine (PEI)-mediated transfections due to the known effectiveness. Many theorize that osmotic pressure plays a role in the stability of the internalized PEI:DNA complex. The rate of in situ complexing and dynamics of the PEI:DNA complexes is dependent on a number of parameters, including osmolality [13]. The increase in osmotic pressure caused by entry of the complex protons into the trafficking endosomes is hypothesized to allow for the release and delivery of the DNA to the target cells. This, along with other variables, must be considered and characterized early in process development to establish reliable and reproducible methods. While not well developed within the cell and gene therapy space, there is evidence to suggest that osmolality is a major factor in effective transfection for a variety of systems, including immunoporation [14] and electroporation [15, 16]. Osmolality influences the ability of buffer solutions to cross cell membranes. As such, it is critical to set specifications around the osmolality of media and transfection cocktails. A delicate balance is required when considering the stability and permeability of the cells to be transfected. The same can be applied during cell lysis, when the goal is to release cell-associated adeno-associated virus (AAV). Osmotic shock is one method to access the genetic material and, as the name implies, it relies heavily on the osmotic pressure of the cellular environment. Incubation at high salt concentrations (high osmolality) can expose the viral genomes but it could also potentially damage them [17].

4. Buffer QC and purification

We recently described osmolality as an orthogonal property of downstream buffers, alongside pH and conductivity [21]. Failure to identify composition issues or deviations in these buffers could result in process and/or product deviations down the line. Osmolality testing should occur during buffer QC and as an in-process parameter during purification. This applies to in-process testing during downstream processing as well. A recent publication described osmolality as a predictor of protein concentration during purification, in conjunction with UV absorbance [22]. This offers a quick and accurate predictive measurement alternative to standard concentration methods that require more time and technical expertise. Earlier identification of impurities saves operational costs and eventual product yield. It remains to be seen how this translates in the gene therapy production workflow, but the role of osmolality as an orthogonal parameter in downstream processing is emerging as a valuable tool.

5. Concentration and buffer exchange

Ultrafiltration/diafiltration (UF/DF) in cell and gene therapy depends on tangential flow filtration (TFF), which has proven advantageous in multiple applications because of the fickleness of advanced therapies [2]. Viruses, especially lentiviruses (LVs), are much larger than mAbs, so getting high recovery and consistent process performance can be difficult. Additionally, achieving high concentrations of viral vector in a drug substance and drug product lends itself to aggregation for enveloped (retrovirus) and non-enveloped (AAV) viruses [2]. Aggregation is especially likely in enveloped viruses, which tend to have a stickier exterior. Filtration operations can damage the membrane of large enveloped viruses, greatly impacting the stability and transduction efficiency of the vector [23]. Osmolality plays a crucial role in reducing the potential for AAV aggregation as well and has been used to check levels of excipients that prevent build-up of AAV2 vectors [24]. UF/DF is also used for buffer exchange within cell and gene therapy workflows. Osmolality testing would help verify the efficiency and completion of these exchanges. Due to the properties of common buffer components, conductivity and pH meters may not have the resolution to capture differences between the starting matrix and final formulation buffer. We have shown that osmolality provides orthogonal value in these situations [21]. Osmolality describes the ability of a solute to cross a membrane, so it is required to give a comprehensive view of solutions during filtration processes.

6. Pre-formulation processing

Osmolality testing is commonly used as a release specification for final formulation buffers, and because cell and gene therapy products are extremely delicate, strict control is required. More novel indications for osmolality, which require additional investigations, are also possible. As mentioned above, sterile filtration of LV is a known pain point due to low recoveries [2], impacting the final filtration and formulation of the drug. Osmolality can serve as a possible indicator for the purity and safety of the end process and final product, as higher osmolalities could eb indicative of unwanted solutes and impurities.

This is particularly useful for viral processing where there is no terminal sterile filtration [25]. Additionally, osmotic pressure could play a role in the hydrodynamic radius of virus and help formulation development teams optimize the molecular weight cutoff for further filtration steps. The role of osmosis and osmotic pressure in viral properties [26], along with evidence with other cell types [27], provide promise for this application. This may be of interest if additional studies are completed to illustrate that variables like osmolality impact filterability for LV through a 0.45 μm or 0.22 μm filter. There is clear evidence that osmotic pressure of the pre-formulation drug substance impacts its filtration and recovery and its characterization could provide the control needed to deliver a high-quality drug product.

7. Final Product Testing

Osmolality testing has long been considered a compendial measurement for the release of biological drugs (FDA), as any substance entering the body must be physiologically isotonic and iso-osmotic. How does this translate to cell therapy, where the cells are the starting and ending material? When specifically discussing cell banking and expansion, comprehensive testing platforms are required to promote optimal identity, safety, purity, and stability [28], key CQAs for which osmolality offers valuable information. These CQAs must be maintained and protected upon cryopreservation, the process of freezing cells for storage of drug intermediates and product [29]. Prior to freezing, adherent cells must be cleanly detached without damaging them.

There is evidence to support the hypothesis that the osmolality of a dissociation agent influences the size of cell aggregates that detach [6]. Freeze/thaw cycles can be detrimental to the cells’ stability and recovery, so cryopreservatives must meet osmolality standards to ensure cell quality and retainment of critical quality attributes are throughout the entire bioprocess. A study was recently completed to test various homemade and commercially available cryopreservatives for osmolality using freezing point depression osmometry.

Understandably, introducing cryoprotectants and freezing cells has a considerable impact on their osmotic pressure [30-32], and repeating this process becomes increasingly complex. Testing the osmolality of the cryopreserves before freezing ensures that the composition is correct and provides confidence in the upcoming preservation steps. Preservation can become critical at multiple stages of therapeutic development, from cell banking through shipping to the clinical environment for injection. Consequently, osmolality testing should be performed at these stages throughout the workflow to ensure cryopreservative properties and protect product CQAs.


The success of cell and gene therapy development is heavily dependent on the strength of its process controls for repeatability and/or scale-up. As the field matures, there will certainly be increased scrutiny from regulatory bodies as expectations around these qualities, as well as product quality, increase. Drug developers must overcome the obstacles of poor process performance. The increased need for robust process control strategies demands reliable and accurate parameters, and osmolality testing fits the bill. Osmolality testing provides a reliable and accurate concentration measurement for solutions throughout the bioprocess. Several applications for this quick and easy test have been outlined here and there is an expectation that more will be uncovered as this field continues to grow.


   1. Medicine, A.f.R. ARM Annual Report & Sector Year in Review: 2019. Advancing Gene, Cell, & Tissue-Based Therapies 2020 [cited 2020 Mar 15].

   2. Forsberg, N.e.a. Key Considerations in Gene Therapy Manufacturing for Commercialization. 2018.

   3. Osmolality and Osmolarity. 2017, US Pharmacopeia.

   4. Osmolality. European Pharmacopeia.

   5. Sweeney, T.E. and C.A. Beuchat, Limitations of methods of osmometry: measuring the osmolality of biological fluids. Am J Physiol, 1993. 264(3 Pt 2): p. R469-80.

   6. Nie, Y., et al., Scalable passaging of adherent human pluripotent stem cells. PLoS One, 2014. 9(1): p. e88012.

   7. Ferreira, T.B., et al., Two different serum-free media and osmolality effect upon human 293 cell growth and adenovirus production. Biotechnol Lett, 2005. 27(22): p. 1809-13.

   8. Stanton, D., Multi-Media Player: GE Invests in EU and US Plants to Tap $1.4bn Market. 2018, Biopharm Intl.

   9. Gilbert, A., Y. Huang, and T. Ryll, Identifying and eliminating cell culture process variability. Pharm. Bioprocess., 2014. 2(6): p. 519-534.

10. Bohnenkamp, H., U. Hilbert, and T. Noll, Bioprocess development for the cultivation of human T-lymphocytes in a clinical scale. Cytotechnology, 2002. 38(1-3): p. 135-45.

11. Potocar, U., et al., Adipose-Derived Stem Cells Respond to Increased Osmolarities. PLoS One, 2016. 11(10): p. e0163870.

12. Koo, J., et al., Controlling medium osmolality improves the expansion of human articular chondrocytes in serum-free media. Tissue Eng Part C Methods, 2010. 16(5): p. 957-63.

13. Gutierrez-Granados, S., et al., Advancements in mammalian cell transient gene expression (TGE) technology for accelerated production of biologics. Crit Rev Biotechnol, 2018. 38(6): p. 918-940.

14. Tzavelas, C., et al., Effect of osmolarity and presence of serum on the efficiency of cell transfection using immunoporation. Anal Cell Pathol, 2001. 22(4): p. 223-7.

15. Golzio, M., et al., Control by osmotic pressure of voltage-induced permeabilization and gene transfer in mammalian cells. Biophys J, 1998. 74(6): p. 3015-22.

16. van den Hoff, M.J., et al., The osmolarity of the electroporation medium affects the transient expression of genes. Nucleic Acids Res, 1990. 18(21): p. 6464.

17. Cordova, A., et al., Osmotic shock and the strength of viral capsids. Biophys J, 2003. 85(1): p. 70-4.

18. Coroadinha, A.S., et al., Effect of osmotic pressure on the production of retroviral vectors: Enhancement in vector stability. Biotechnol Bioeng, 2006. 94(2): p. 322-9.

19. Rodrigues, A., P.M. Alves, and A.S. Coroadinha, Production of Retroviral and Lentiviral Gene Therapy Vectors: Challenges in the Manufacturing of Lipid Enveloped Virus, in Viral Gene Therapy, K. Xu, Editor. 2011, Intech. p. 15-40.

20. Amaral, A.I., et al., Improving retroviral vectors production: role of carbon sources in lipid biosynthesis. J Biotechnol, 2008. 138(3-4): p. 57-66.

21. Wright, K., Osmolality as a concentration measurement method for key buffers in bioprocessing. 2019, Advanced Instruments.

22. Felfodi, E., et al., Osmolality is a predictor for model-based real time monitoring of concentration in protein chromatography. Journal of Chem Tech & Biotech, 2019.

23. Morenweiser, R., Downstream processing of viral vectors and vaccines. Gene Ther, 2005. 12 Suppl 1: p. S103-10.

24. Wright, J., et al., Identification of factors that contribute to recombinant AAV2 particle aggregation and methods to prevent its occurrence during vector purification and formulation. Molecular Therapy, 2005. 12(1): p. 171-178.

25. Moleirinho, M.G., et al., Current challenges in biotherapeutic particles manufacturing. Expert Opin Biol Ther, 2020. 20(5): p. 451-465.

26. Choi, H.J., et al., Effect of Osmotic Pressure on the Stability of Whole Inactivated Influenza Vaccine for Coating on Microneedles. PLoS One, 2015. 10(7): p. e0134431.

27. Rosinski, M., S. Reid, and L.K. Nielsen, Osmolarity effects on observed insect cell size after baculovirus infection are avoided using growth medium for sample dilution. Biotechnol Prog, 2000. 16(5): p. 782-5.